- Home
- HCM
as of 10-09-2026 1:05pm EST
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
| Founded: | 2000 | Country: | Hong Kong |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.3B | IPO Year: | 2015 |
| Target Price: | $22.01 | AVG Volume (30 days): | 52.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $9.77 - $16.33 | Next Earning Date: | 07-30-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 14.24% | Revenue Growth (next year): | 11.52% |
| P/E Ratio: | 5.49 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Compare HCM vs Leading Stocks
See how HCM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "HCM HUTCHMED (China) Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.